Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma | BMC Cancer | Full Text

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma | BMC Cancer | Full Text

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a dismal response to single-use of immune checkpoint inhibitors (ICIs). ICIs combined with systemic therapy has shown efficacy and safety in vari...

Authors:Lin Shui, Ke Cheng, Xiaofen Li, Pixian Shui, Xiaohan Zhou, Jian Li, Cheng Yi and Dan Cao

Citation:BMC Cancer 2020 20:636

Content type:Study protocol

 

Published on: 9 July 2020

• ViewFull Text
 
• ViewPDF